MAIA Biotechnology, Inc.
ASE: MAIALive Quote
About MAIA Biotechnology, Inc.
Healthcare
Biotechnology
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
📊 Fundamental Analysis
MAIA Biotechnology, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -745.2%, which indicates that capital utilization is currently under pressure.
At a current price of $1.28, MAIA currently trades near the bottom of its 52-week range (18%), indicating potential value or weakness (Range: $0.87 - $3.19).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$79.04M
Trailing P/E
--
Forward P/E
0.47
Beta (5Y)
0.32
52W High
$3.19
52W Low
$0.87
Avg Volume
1.11M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App